Dr Ferdy van Geest, (Erasmus Medical Center, Rotterdam, The Netherlands) kindly spoke with us about the results of his study investigating Triac in patients with MCT8.
The abstract entitled ‘Long-term efficacy of triiodothyronine analogue Triac in children and adults with monocarboxylate transporter 8 deficiency: an international, real-life cohort study’ (Abstract 82) was given at European Thyroid Association (ETA) Annual Meeting 2021, 4–7 September.
1. What clinical characteristics do patients with monocarboxylate transporter MCT8 deficiency display? (0:35)
2. Please describe the mechanism of action of Triac and what has been previously established regarding efficacy and safety in patients with MCT8 deficiency? (2:19)
3. What further evidence did this real-life cohort study aim to gather? (4:02)
4. What were the key results of the study? (6:06)
5. How will Triac impact the treatment of patients with MCT8 deficiency? (7:06)
Disclosures: The Erasmus Medical Center (Rotterdam, Netherlands), which employs FSvG, receives royalties from Rare Thyroid Therapeutics (the manufacturer of Triac), dependent on commercialization. None of the authors will benefit personally from any royalties. Rare Thyroid Therapeutics had no influence on the conduct or analysis of this study.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Louise Taylor.
Filmed in coverage of the European Thyroid Association (ETA) Annual Meeting 2021, 4–7 September 2021.
van Geest F, Groeneweg S, van Toor H, et al. 82: Long-term efficacy of triiodothyronine analogue Triac in children and adults with monocarboxylate transporter 8 deficiency: an international, real-life cohort study. Eur Thyroid J 2021;10(Suppl. 1):6.
Share this Video
Related Videos In Thyroid Disorders
Glenn Braunstein: Research highlights from 2022
We were delighted to speak with our editorial board member Prof. Glenn Braunstein (Cedars-Sinai Medical Center, Los Angeles, CA, USA) around this year’s research highlights in thyroid disorders and what to look out for in 2023. Questions What are the key clinical highlights from 2022 in the field of thyroid disorders? (0:14) What are the […]
Kristien Boelaert, ATA 2022: The EGRET study: Long term mortality and cardiometabolic effects of hyperthyroidism treatment
Current evidence indicates cardio‐metabolic effects from antithyroid drugs and other definitive treatment options for hyperthyroidism. The EGRET study aimed to assess the differences in mortality and cardiometabolic outcomes depending on the method of treatment in order to better inform patient‐clinician decision‐making. In this touchENDOCRINOLOGY interview, Prof. Kristien Boelaert (University of Birmingham, Birmingham, United Kingdom) discusses […]
Kristien Boelaert, ATA 2022: Challenges of the long term treatment of hyperthyroidism
Hyperthyroidism, also called overactive thyroid, occurs when your thyroid gland overproduces thyroid hormones. In this touchENDOCRINOLOGY interview, Prof. Kristien Boelaert (University of Birmingham, Birmingham, United Kingdom) discusses the challenges faced in the long term treatment of hyperthyroidism. The abstract entitled: ‘LONG‐TERM MORTALITY AND CARDIOMETABOLIC EFFECTS OF TREATMENT FOR HYPERTHYROIDISM: EGRET STUDY‘ was presented at the American […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!